Successor drug to Vioxx faces uphill battle in FDA approval
Vioxx's maker, Merck & Co., is asking the Food and Drug Administration to approve a successor to the pulled drug Vioxx that was found to increase the risk of heart attack and stroke. This week, an FDA advisory committee will hold a public meeting on the new drug Arcoxia, a Cox-2 inhibitor. The FDA is expected to rule before May on whether to the Vioxx successor.
For the full article.
Bookmark: 
